Wanbang Pharmaceutical Holding Group (002082.SZ) subsidiary drug WP107 obtains ethical approval.

Wanbangde Pharmaceutical Holding Group (002082.SZ) announced that its wholly-owned subsidiary, Wanbangde Pharmaceutical Holding Group Pharmaceutical Group Co., Ltd., has received approval from the Medical Ethics Committee of the Second Affiliated Hospital of Wenzhou Medical University and the Affiliated English Children's Hospital of Wenzhou Medical University to conduct Phase I clinical trials for the new drug WP107 for the treatment of myasthenia gravis. After receiving the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration, the company has actively proceeded with pharmaceutical and clinical work, and has officially started Phase I clinical trial work. The approval from the Medical Ethics Committee is to compare the pharmacokinetic characteristics of oral Sanchaine A and intravenous Sanchaine A in healthy Chinese subjects under fasting conditions, and to assess the relative bioavailability of oral Sanchaine A and the safety of the two formulations under fasting conditions.